BASKHANBIOPharma Inc.

As of December 31, 2025, BASKHANBIOPharma Inc. carries a market capitalization of 33.55B, placing it among publicly traded companies globally. Its enterprise value stands at 25.15B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, BASKHANBIOPharma Inc. has 7.02M shares outstanding.

As of December 31, 2025, BASKHANBIOPharma Inc. trades at a trailing price-to-earnings ratio of 7.04. The price-to-sales ratio is 1.00, and the price-to-book ratio stands at 0.93.

As of December 31, 2025, BASKHANBIOPharma Inc. trades at an EV/EBITDA multiple of 5.24 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.75 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 8.69 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 25.15B versus a market cap of 33.55B, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2025, BASKHANBIOPharma Inc. maintains a current ratio of 6.87, meaning it holds 6.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.48, indicating conservative leverage, while an interest coverage ratio of 223.91 demonstrates strong ability to service its debt obligations.

Over the twelve months ended December 31, 2025, BASKHANBIOPharma Inc. posted a return on equity (ROE) of 14.37, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 12.61, measuring how efficiently the asset base is converted into earnings. The company generates approximately 294.04M in revenue per employee across its workforce of 114.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.53 indicates how many times BASKHANBIOPharma Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended December 31, 2025, BASKHANBIOPharma Inc. recorded an income tax benefit of -1.53B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 3.23B, leaving 4.77B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, BASKHANBIOPharma Inc.'s stock has declined approximately 30.57% over the past 52 weeks. The 50-day moving average sits at 3,574.00, while the 200-day moving average is 4,219.00.

Over the twelve months ended December 31, 2025, BASKHANBIOPharma Inc. generated 33.52B in revenue and converted that into 4.77B in net income, yielding earnings per share of 679.15. EBITDA reached 4.80B, while operating income came in at 2.89B.

As of December 31, 2025, BASKHANBIOPharma Inc. holds 8.57B in cash and equivalents against 172.89M in total debt, resulting in a net debt position of -3.54B. Total book value stands at 36.14B, with working capital of 21.14B providing operational flexibility.

BASKHANBIOPharma Inc. produced 4.09B in operating cash flow over the twelve months ended December 31, 2025. After subtracting -726.25M in capital expenditures, free cash flow totaled 3.36B - equivalent to 479.03 per share.

Over the twelve months ended December 31, 2025, BASKHANBIOPharma Inc. posted a gross margin of 26.97, reflecting its pricing power and cost economics. The operating margin of 8.64 and net profit margin of 14.22 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2025. Free cash flow yield stands at 10.02, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.52, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to BASKHANBIOPharma Inc. shareholders.

As of December 31, 2025, BASKHANBIOPharma Inc. has an Altman Z-Score of 6.29, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.